Motus GI (MOTS) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38389
Entity Registrant Name	Motus GI Holdings, Inc.
Entity Central Index Key	0001686850
Entity Tax Identification Number	81-4042793
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1301 East Broward Boulevard
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33301
City Area Code	(954)
Local Phone Number	541 8000
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	MOTS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,893,453

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,521	$ 14,042
Accounts receivable	106	59
Inventory, current	446	488
Prepaid expenses and other current assets	737	781
Total current assets	9,810	15,370
Fixed assets, net	1,209	1,325
Inventory, non-current	377	511
Right-of-use assets	332	428
Other non-current assets	13	13
Total assets	11,741	17,647
Current liabilities:
Current portion of long-term debt, net of unamortized debt discount of $151 and $182, respectively	2,694	2,532
Accounts payable and accrued expenses	1,470	1,969
Operating lease liabilities – current	243	245
Other current liabilities	44	53
Total current liabilities	4,451	4,799
Convertible note, net of unamortized debt discount of $80 and $108, respectively	3,920	3,892
Long-term debt, net of unamortized debt discount of $70 and $135, respectively	3,198	4,589
Contingent royalty obligation	1,056	1,212
Operating lease liabilities - non-current	79	178
Total liabilities	12,704	14,670
Commitments and contingent liabilities (Note 9)
Shareholders’ (deficiency) equity
Common stock $0.0001 par value; 115,000,000 shares authorized; 5,305,441 and 4,659,769 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	1
Additional paid-in capital	147,770	144,328
Accumulated deficit	(148,734)	(141,351)
Total shareholders’ (deficiency) equity	(963)	2,977
Total liabilities and shareholders’ (deficiency) equity	$ 11,741	$ 17,647

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount	$ 151	$ 182
Convertible note, unamortized discount, non-current	80	108
Debt instrument, unamortized discount, non-current	$ 70	$ 135
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	115,000,000	115,000,000
Common stock, shares issued	5,305,441	4,659,769
Common stock, shares outstanding	5,305,441	4,659,769

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 113	$ 185	$ 169	$ 205
Operating expenses:
Cost of revenue - sales	31	68	40	83
Cost of revenue - impairment of inventory	30		195	159
Research and development	759	1,413	2,213	2,688
Sales and marketing	337	1,222	1,179	2,205
General and administrative	1,638	2,075	3,583	4,189
Total costs and expenses	2,795	4,778	7,210	9,324
Loss from Operations	(2,682)	(4,593)	(7,041)	(9,119)
Gain (loss) on change in estimated fair value of contingent royalty obligation	(64)	(92)	156	(63)
Finance expense, net	(246)	(359)	(485)	(691)
Foreign currency loss	(5)	(96)	(13)	(78)
Net loss	$ (2,997)	$ (5,140)	$ (7,383)	$ (9,951)
Basic loss per common share:	$ (0.40)	$ (1.86)	$ (1.20)	$ (3.72)
Diluted loss per common share	$ (0.40)	$ (1.86)	$ (1.20)	$ (3.72)
Weighted average number of common shares outstanding, basic	7,555,903	2,758,457	6,167,271	2,674,536
Weighted average number of common shares outstanding, diluted	7,555,903	2,758,457	6,167,271	2,674,536

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance, value at Dec. 31, 2021		$ 132,411	$ (122,754)	$ 9,657
Balance, shares at Dec. 31, 2021	2,416,021
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $5		3,004		3,004
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	298,761
Share-based compensation		521		521
Net loss			(4,811)	(4,811)
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	13,721
Issuance of common stock for board of directors’ compensation		235		235
Issuance of common stock for board of directors' compensation, shares	24,458
Balance, value at Mar. 31, 2022		136,171	(127,565)	8,606
Balance, shares at Mar. 31, 2022	2,752,961
Balance, value at Dec. 31, 2021		132,411	(122,754)	9,657
Balance, shares at Dec. 31, 2021	2,416,021
Net loss				(9,951)
Balance, value at Jun. 30, 2022		136,677	(132,705)	3,972
Balance, shares at Jun. 30, 2022	2,765,259
Balance, value at Mar. 31, 2022		136,171	(127,565)	8,606
Balance, shares at Mar. 31, 2022	2,752,961
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $5		45		45
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	8,124
Share-based compensation		461		461
Net loss			(5,140)	(5,140)
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	4,174
Balance, value at Jun. 30, 2022		136,677	(132,705)	3,972
Balance, shares at Jun. 30, 2022	2,765,259
Balance, value at Dec. 31, 2022		144,328	(141,351)	2,977
Balance, shares at Dec. 31, 2022	4,659,769
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs of $5		102		102
Issuance of common shares pursuant to at-the-market registered offering, net of issuance costs, shares	119,104
Share-based compensation		222		222
Net loss			(4,386)	(4,386)
Balance, value at Mar. 31, 2023		144,652	(145,737)	(1,085)
Balance, shares at Mar. 31, 2023	4,778,873
Balance, value at Dec. 31, 2022		144,328	(141,351)	2,977
Balance, shares at Dec. 31, 2022	4,659,769
Net loss				(7,383)
Balance, value at Jun. 30, 2023	$ 1	147,770	(148,734)	(963)
Balance, shares at Jun. 30, 2023	5,305,441
Balance, value at Mar. 31, 2023		144,652	(145,737)	(1,085)
Balance, shares at Mar. 31, 2023	4,778,873
Share-based compensation		49		49
Net loss			(2,997)	(2,997)
Private placement offering, net of financing fees of $731	$ 1	3,069		3,070
Private placement offering, shares	525,000
Issuance of common shares upon vesting of restricted stock units
Issuance of common shares upon vesting of restricted stock units, shares	1,568
Balance, value at Jun. 30, 2023	$ 1	$ 147,770	$ (148,734)	$ (963)
Balance, shares at Jun. 30, 2023	5,305,441

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 731	$ 19	$ 5	$ 111

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,383)	$ (9,951)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	230	253
Amortization of debt issuance costs	123	125
Gain (loss) on change in estimated fair value of contingent royalty obligation	(156)	63
Share based compensation	271	982
Impairment of inventory	195	159
Impairment of fixed assets		36
Issuance of common stock for board of directors’ compensation		118
Amortization on operating lease right-of-use asset	121	175
Changes in operating assets and liabilities:
Accounts receivable	(47)	28
Inventory	(33)	(764)
Prepaid expenses and other current assets	44	(407)
Accounts payable and accrued expenses	(604)	(459)
Operating lease liabilities – current and non-current	(125)	(177)
Other current and non-current liabilities	(9)	8
Net cash used in operating activities	(7,373)	(9,811)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(88)	(49)
Net cash used in investing activities	(88)	(49)
CASH FLOWS FROM FINANCING ACTIVITIES:
Gross proceeds from private placement offering	3,537
Repayment of debt	(1,325)
Proceeds from issuance of common shares pursuant to at-the-market issuance registered offering	121	3,165
Equity financing fees	(393)	(111)
Net cash provided by financing activities	1,940	3,054
NET DECREASE IN CASH AND CASH EQUIVALENTS	(5,521)	(6,806)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	14,042	22,563
CASH AND CASH EQUIVALENTS AT END OF PERIOD	8,521	15,757
CASH PAID FOR:
Interest	476	511
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Common stock issued to settle accrued expenses for board of directors’ compensation
Common stock issued for prepaid board of directors’ compensation		117
Reclassification of prepaid expenses to fixed assets		4
Reclassification of inventory to fixed assets	14	62
Purchase of fixed assets in accounts payable and accrued expenses	12	75
Financing fees included in accounts payable and accrued expenses	93	5
Non-cash issuance costs from private placement	264
Right-of-use asset obtained in exchange for lease obligation	35	34
Prepaid expenses resulting from right-of-use asset obtained		$ 3

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”. The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced commercialization of this product. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.

Basis of Presentation and Going

Basis of Presentation and Going Concern Uncertainty	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Going Concern Uncertainty	Note 2 – Basis of Presentation and Going Concern Uncertainty The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2022 10-K filed with the SEC on March 31, 2023. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2022 condensed consolidated balance sheet information was derived from the audited financial statements as of that date. The Company has generated limited revenues to date from the sale of products. The Company has never been profitable and has incurred significant net losses each year since its inception, including a loss of $ 7.4 7.3 8.5 148.7 In January and April 2023, the Company committed to a restructuring initiative designed to position the Company to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating the commercialization of the Pure-Vu System. If a strategic transaction is not completed, or if additional financing is not available, the Company may not be able to service our outstanding indebtedness and our payables and may have to file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of the Company’s remaining assets. In such an event, the amount of cash available for distribution to the Company’s shareholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as the Company continues to fund its operations and service the Company’s outstanding indebtedness. The Company cannot provide assurance as to the amount of cash that will be available to distribute to shareholders, if any, after paying its debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any. Such conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that may result from this uncertainty. The Company has financed its operations primarily through sales of equity-related securities. In March 2021, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), under which we may offer and sell from time to time common shares having an aggregate offering price of up to $ 25.0 119 102 19 On May 17, 2023, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to issue and sell in a private placement an aggregate of (i) 525,000 shares of common stock, (ii) warrants to purchase up to 3,617,012

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements for the six months ended June 30, 2023 are consistent with those discussed in Note 3 to the consolidated financial statements in the Company’s 2022 Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the six months ended June 30, 2023. Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive, using the treasury stock method. The Company’s net loss is net loss attributable to common shareholders for all periods presented. The Company would use the two-class method to compute net income per common share, as it issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. The two-class method presentation will only be required if and when the Company reports net income. Given the nominal exercise price of the Company’s issuance of pre-funded warrants, such pre-funded warrants are included in in the calculation of basic and diluted net loss per share as the exercise price per warrant is deemed nonsubstantive when compared to the fair value of the underlying common shares. The 3,617,012 The Company’s Convertible Note, on an as converted basis into common stock of 142,857 SCHEDULE OF ANTI-DILUTIVE EFFECT 2023 2022 2023 2022 Three Months Ended Six Months Ended 2023 2022 2023 2022 Outstanding options 304,164 403,911 304,164 403,911 Unvested restricted stock units 10,455 28,613 10,455 28,613 Warrants 4,686,657 394,577 4,686,657 394,577 Total 5,001,276 827,101 5,001,276 827101 Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company had a full valuation allowance against its deferred tax assets. For the three and six months ended June 30, 2023 and 2022, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and six months ended June 30, 2023 and 2022, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses. Accounting Pronouncements- Adopted In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this ASU on January 1, 2023. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures. Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements Liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 30, 2023 and December 31, 2022: Schedule of Fair Value of Financial Assets and Liabilities June 30, 2023 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,056 $ 1,056 December 31, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,212 $ 1,212 Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, and certain other current liabilities, due to their short-term nature. Debt instruments are measured at amortized cost on the Company’s consolidated balance sheets. If measured at fair value in the financial statements, these instruments would be classified as Level 2 in the fair value hierarchy. In estimating the fair value of the Company’s contingent royalty obligation, the Company used the discounted cash flow method as of June 30, 2023 and December 31, 2022. Based on the fair value hierarchy, the Company classified contingent royalty obligation within Level 3 because valuation inputs are based on projected revenues discounted to a present value. Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the six months ended June 30, 2023 was as follows: Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation Fair Value Balance at December 31, 2022 $ 1,212 Change in estimated fair value of contingent royalty obligation 156 Balance at June 30, 2023 $ 1,056 The contingent royalty obligation is re-measured at each balance sheet date using several assumptions, including the following: 1) estimated sales growth, 2) length of product cycle, 3) patent life, 4) discount rate ( 28.5 23 3 In accordance with ASC-820-10-50-2(g), the Company performed a sensitivity analysis of the liability, which was classified as a Level 3 financial instrument. The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $95 and a 2% increase in the discount rate would decrease the liability by $86. Such amounts are based on highly sensitive estimates and actual results could result in material change in future periods

Inventory

Inventory	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory is stated at lower of cost or net realizable value using the weighted average cost method and is evaluated at least annually for impairment. Write-downs for potentially obsolete or excess inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts. For the three and six months ended June 30, 2023, an inventory impairment of $ 30 195 0 159 Inventory at June 30, 2023 and December 31, 2022 consisted of the following: Schedule of Inventory June 30, 2023 December 31, 2022 Raw materials $ 553 $ 697 Work-in-process 177 155 Finished goods 689 548 Inventory reserve (596 ) (401 ) Inventory, net $ 823 $ 999 Inventory, current $ 446 $ 488 Inventory, non-current $ 377 $ 511

Fixed assets, net

Fixed assets, net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Fixed assets, net	Note 6 – Fixed assets, net Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net June 30, 2023 December 31, 2022 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,056 1,049 Lab and medical equipment 1,584 1,477 Leasehold improvements 200 200 Total 3,332 3,218 Less: accumulated depreciation and amortization (2,123 ) (1,893 ) Fixed assets, net $ 1,209 $ 1,325 Depreciation and amortization expense for the three and six months ended June 30, 2023 was $ 113 230 129 253

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases
Leases	Note 7 – Leases The Company leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2023 leases vehicles under operating leases that expire at various dates through 2025 The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2023 2022 2023 2022 Three Months ended June 30, Six Months ended June 30, 2023 2022 2023 2022 Lease Cost Operating lease cost, net of related party license fee $ 2 $ 23 $ 18 $ 62 Variable lease cost 39 30 64 60 Total lease cost $ 41 $ 53 $ 82 $ 122 As of As of Assets Operating lease, right-of-use- asset $ 332 $ 428 Liabilities Current Operating lease liabilities $ 243 $ 245 Non-current Operating lease liabilities, net of current portion 79 178 Total lease liabilities $ 322 $ 423 Other information: Weighted average remaining lease term - operating leases 1.44 1.79 Weighted-average discount rate - operating leases 7.30 % 7.36 % The Company’s lease expense is included in general and administrative expenses which is net of the related party license fee of $ 60 109 107

Convertible Note and Long-Term

Convertible Note and Long-Term Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Convertible Note and Long-Term Debt	Note 8 – Convertible Note and Long-Term Debt On July 16, 2021 (the “Effective Date”), the Company entered into a loan facility (the “Kreos Loan Agreement”) with Kreos Capital VI (Expert Fund) LP (the “Lender”). Under the Kreos Loan Agreement, the Lender will provide the Company with access to term loans in an aggregate principal amount of up to $ 12,000 4,000 5,000 3,000 The Convertible Note and Tranche B were funded on the Effective Date. As of December 31, 2021, the Company drew down the full $ 3,000 The Convertible Note requires forty-eight monthly interest only payments at 7.75 28 7.75 In connection with the Kreos Loan Agreement, the Company also issued to the Lender a warrant (“Warrant”), dated July 16, 2021, to purchase up to 9,547 20.948 The Company treated Tranche A, Tranche B and Tranche C, and the Warrant as three separate freestanding financial instruments with the proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value. The proceeds received in connection with the transaction allocated amongst the instruments based on relative fair value resulted in $ 165 845 165 540 274 140 845 For the six months ended June 30, 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 470 Amortization of debt issuance costs 123 Total interest expense $ 593 For the three months ended June 30, 2023, interest expense for the Loan was as follows: Contractual interest expense $ 224 Amortization of debt issuance costs 61 Total interest expense $ 285 Future principal payments under the Convertible Note as of June 30, 2023 are as follows: Schedule of Future Principal Payments of Convertible Note Years Ending December 31, Amount 2023 (remaining 6 months) $ - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs (80 ) Total balance – Convertible Note $ 3,920 Future principal payments under the Long-term Debt as of June 30, 2023 are as follows: Years Ending December 31, Amount 2023 (remaining 6 months) $ 1,389 2024 2,983 2025 1,601 Total future principal payments 5,973 End of loan payments 140 Less unamortized debt issuance costs of current portion of long-term debt (151 ) Less unamortized debt issuance costs of non-current portion of long-term debt (70 ) Total balance $ 5,892 Less long-term debt, current $ 2,694 Long- term debt, net of current portion $ 3,198

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies The Company has entered into and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its research and development efforts. Significant agreements are described in detail in the Company’s 2022 Form 10-K. While specific amounts will differ from quarter to quarter, the Company believes its overall activities regarding these agreements are materially consistent with those described in the 2022 Form 10-K. In addition to the specific agreements described in the 2022 Form 10-K, the Company has entered into, and will in the future enter into, other research and service provider agreements for the advancement of its research and development efforts. The Company expects to pay additional amounts in future periods in connection with existing and future research and service provider agreements. Manufacturing Component Purchase Obligations The Company utilizes two outsourcing partners to manufacture its workstation and disposable portions of the Pure-Vu System, and to perform final assembly and testing of finished products. These outsourcing partners acquire components and build product based on demand information supplied by the Company. As of June 30, 2023, the Company expects to pay $ 38

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions Shared Space Agreement In January 2020, the Company entered into a license agreement (the “Shared Space Agreement”) with Orchestra BioMed, Inc. (OBIO), formerly a greater than 5 212 270 60 109 60 107

Share-based compensation

Share-based compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation	Note 11 – Share-based compensation The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and six months ended June 30, 2023 and 2022: Schedule of Stock-based Compensation 2023 2022 2023 2022 Three Months ended June 30, Six Months ended June 30, 2023 2022 2023 2022 Research and development $ 21 $ 100 $ 80 $ 197 Sales and marketing - 65 1 123 General and administrative 28 296 190 662 Total $ 49 $ 461 $ 271 $ 982 As of June 30, 2023, unamortized share-based compensation for stock options was $ 243 0.68 Stock option and warrant activity A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2022 400,137 $ 42.69 393,261 $ 50.86 Granted - - * 7,966,125 * $ 0.40 Expired (46,132 ) $ 42.87 (55,717 ) $ 100.45 Forfeited (49,841 ) $ 13.45 - $ - Outstanding at June 30, 2023 304,164 $ 47.45 8,303,669 $ 0.61 Exercisable at June 30, 2023 278,971 $ 50.43 8,303,669 $ 0.61 * Includes 3,617,012 0.0001 As of June 30, 2023, there were 10,455 5.74 20,278 18.62 As of June 30, 2023, unamortized stock compensation for restricted stock units was $ 50 0.68 Issuance of Warrants to Purchase Common Stock In February 2020, the Company entered into a services agreement whereby it agreed to issue warrants to purchase 6,000 56.60 6,000 10 0 26 On May 17, 2023, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it agreed to issue and sell in a private placement an aggregate of (i) 525,000 3,617,012 4,142,012 0.845 0.8449 3.0 0.5 0.2 0.72 0.0001 The measurement of fair value of the Pre-Funded Warrants was determined utilizing a Black-Scholes model. The relative fair value of these Pre-Funded Warrants was estimated to be $ 1.7 The measurement of fair value of the Common Warrants was determined utilizing a Black-Scholes model. The relative fair value of these Common Stock Warrants was estimated to be $ 1.5 In addition, pursuant to the terms of the offering, the Company issued the placement agent, H.C. Wainwright & Co., LLC., warrants to purchase up to 207,101 shares of the Company’s common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are exercisable for a period of five and one-half years from the issuance date, at an exercise price of $ 1.0563 0.1 As of August 14, 2023, Pre-Funded Warrants for 588,012 Additionally, in connection with the Private Placement, the Company entered into a warrant amendment (the “Warrant Amendment”), dated May 17, 2023 with the holder named therein, pursuant to which the Company agreed to amend certain existing warrants to purchase up to an aggregate of 299,997 42.40 after the 1-to-20 reverse stock split 0.72 0.125 0.1 The Private Placement resulted in net proceeds of approximately $ 3.0 0.5 0.2

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Note 12 – Restructuring In January 2023, the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date 267 1,517 416 1,423 94 The outstanding restructuring liabilities are included in accounts payable and accrued expenses on the condensed consolidated balance sheet. As of June 30, 2023, the components of the liabilities were as follows: Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses Employee (1) Balance as of January 1, 2023 $ - Restructuring expenses- Sales and Marketing 566 Restructuring expenses- Research and Development 477 Restructuring expenses- General and Administrative 474 Restructuring expenses Cash payments (1,423 ) Liability included in accounts payable and accrued expenses at June 30, 2023 $ 94 (1) Employee severance and other benefits expenses were included in sales and marketing expenses, research and development expenses, and general and administrative expenses in the statements of comprehensive loss.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and include the accounts of the Company and its wholly owned subsidiaries, Motus Ltd., an Israel corporation, which has operations in Tirat Carmel, Israel, and Motus Inc., a Delaware corporation, which has operations in the U.S. All inter-company accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basic and diluted net loss per share	Basic and diluted net loss per share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the applicable period, including any potentially dilutive securities such as stock options, unvested restricted stock, warrants, and other convertible instruments unless the result of inclusion would be antidilutive, using the treasury stock method. The Company’s net loss is net loss attributable to common shareholders for all periods presented. The Company would use the two-class method to compute net income per common share, as it issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. The two-class method presentation will only be required if and when the Company reports net income. Given the nominal exercise price of the Company’s issuance of pre-funded warrants, such pre-funded warrants are included in in the calculation of basic and diluted net loss per share as the exercise price per warrant is deemed nonsubstantive when compared to the fair value of the underlying common shares. The 3,617,012 The Company’s Convertible Note, on an as converted basis into common stock of 142,857 SCHEDULE OF ANTI-DILUTIVE EFFECT 2023 2022 2023 2022 Three Months Ended Six Months Ended 2023 2022 2023 2022 Outstanding options 304,164 403,911 304,164 403,911 Unvested restricted stock units 10,455 28,613 10,455 28,613 Warrants 4,686,657 394,577 4,686,657 394,577 Total 5,001,276 827,101 5,001,276 827101
Income taxes	Income taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company had a full valuation allowance against its deferred tax assets. For the three and six months ended June 30, 2023 and 2022, the Company recorded zero income tax expense. No tax benefit has been recorded in relation to the pre-tax loss for the three and six months ended June 30, 2023 and 2022, due to a full valuation allowance to offset any deferred tax asset related to net operating loss carry forwards attributable to the losses.
Accounting Pronouncements- Adopted	Accounting Pronouncements- Adopted In September 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments” and ASU No. 2019-05, “Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief” which provided additional implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date for public filers that are considered smaller reporting companies as defined by the Securities and Exchange Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this ASU on January 1, 2023. The adoption of this ASU did not result in a material impact to the consolidated financial statements and disclosures.
Accounting Pronouncements- Not Yet Adopted	Accounting Pronouncements- Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF ANTI-DILUTIVE EFFECT	SCHEDULE OF ANTI-DILUTIVE EFFECT 2023 2022 2023 2022 Three Months Ended Six Months Ended 2023 2022 2023 2022 Outstanding options 304,164 403,911 304,164 403,911 Unvested restricted stock units 10,455 28,613 10,455 28,613 Warrants 4,686,657 394,577 4,686,657 394,577 Total 5,001,276 827,101 5,001,276 827101

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	Liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 30, 2023 and December 31, 2022: Schedule of Fair Value of Financial Assets and Liabilities June 30, 2023 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,056 $ 1,056 December 31, 2022 Level 1 Level 2 Level 3 Fair Value Liabilities Contingent royalty obligation $ - $ - $ 1,212 $ 1,212
Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation	Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of a contingent royalty obligation, during the six months ended June 30, 2023 was as follows: Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation Fair Value Balance at December 31, 2022 $ 1,212 Change in estimated fair value of contingent royalty obligation 156 Balance at June 30, 2023 $ 1,056

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at June 30, 2023 and December 31, 2022 consisted of the following: Schedule of Inventory June 30, 2023 December 31, 2022 Raw materials $ 553 $ 697 Work-in-process 177 155 Finished goods 689 548 Inventory reserve (596 ) (401 ) Inventory, net $ 823 $ 999 Inventory, current $ 446 $ 488 Inventory, non-current $ 377 $ 511

Fixed assets, net (Tables)

Fixed assets, net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets Net	Fixed assets, summarized by major category, consist of the following for the years ended: Schedule of Fixed Assets Net June 30, 2023 December 31, 2022 Office equipment $ 171 $ 171 Computers and software 321 321 Machinery 1,056 1,049 Lab and medical equipment 1,584 1,477 Leasehold improvements 200 200 Total 3,332 3,218 Less: accumulated depreciation and amortization (2,123 ) (1,893 ) Fixed assets, net $ 1,209 $ 1,325

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases
Schedule of Lease Cost and Supplemental Balance Sheet Information	The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows: Schedule of Lease Cost and Supplemental Balance Sheet Information 2023 2022 2023 2022 Three Months ended June 30, Six Months ended June 30, 2023 2022 2023 2022 Lease Cost Operating lease cost, net of related party license fee $ 2 $ 23 $ 18 $ 62 Variable lease cost 39 30 64 60 Total lease cost $ 41 $ 53 $ 82 $ 122 As of As of Assets Operating lease, right-of-use- asset $ 332 $ 428 Liabilities Current Operating lease liabilities $ 243 $ 245 Non-current Operating lease liabilities, net of current portion 79 178 Total lease liabilities $ 322 $ 423 Other information: Weighted average remaining lease term - operating leases 1.44 1.79 Weighted-average discount rate - operating leases 7.30 % 7.36 %

Convertible Note and Long-Ter_2

Convertible Note and Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Interest Expense for Loan	For the six months ended June 30, 2023, interest expense for the Loan was as follows: Schedule of Interest Expense for Loan Contractual interest expense $ 470 Amortization of debt issuance costs 123 Total interest expense $ 593 For the three months ended June 30, 2023, interest expense for the Loan was as follows: Contractual interest expense $ 224 Amortization of debt issuance costs 61 Total interest expense $ 285
Schedule of Future Principal Payments of Convertible Note	Future principal payments under the Convertible Note as of June 30, 2023 are as follows: Schedule of Future Principal Payments of Convertible Note Years Ending December 31, Amount 2023 (remaining 6 months) $ - 2024 - 2025 4,000 Total future principal payments 4,000 Less unamortized debt issuance costs (80 ) Total balance – Convertible Note $ 3,920 Future principal payments under the Long-term Debt as of June 30, 2023 are as follows: Years Ending December 31, Amount 2023 (remaining 6 months) $ 1,389 2024 2,983 2025 1,601 Total future principal payments 5,973 End of loan payments 140 Less unamortized debt issuance costs of current portion of long-term debt (151 ) Less unamortized debt issuance costs of non-current portion of long-term debt (70 ) Total balance $ 5,892 Less long-term debt, current $ 2,694 Long- term debt, net of current portion $ 3,198

Share-based compensation (Table

Share-based compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation	The following table sets forth total non-cash share-based compensation for the issuance of common stock, options to purchase common stock, warrants to purchase common stock, and restricted stock unit awards by operating statement classification for the three and six months ended June 30, 2023 and 2022: Schedule of Stock-based Compensation 2023 2022 2023 2022 Three Months ended June 30, Six Months ended June 30, 2023 2022 2023 2022 Research and development $ 21 $ 100 $ 80 $ 197 Sales and marketing - 65 1 123 General and administrative 28 296 190 662 Total $ 49 $ 461 $ 271 $ 982
Schedule of Stock Option and Warrants	A summary of the Company’s stock option and warrant activity is as follows: Schedule of Stock Option and Warrants Options Warrants Shares Underlying Options Weighted Average Exercise Price Shares Underlying Warrants Weighted Average Exercise Price Outstanding at December 31, 2022 400,137 $ 42.69 393,261 $ 50.86 Granted - - * 7,966,125 * $ 0.40 Expired (46,132 ) $ 42.87 (55,717 ) $ 100.45 Forfeited (49,841 ) $ 13.45 - $ - Outstanding at June 30, 2023 304,164 $ 47.45 8,303,669 $ 0.61 Exercisable at June 30, 2023 278,971 $ 50.43 8,303,669 $ 0.61 * Includes 3,617,012 0.0001

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses	The outstanding restructuring liabilities are included in accounts payable and accrued expenses on the condensed consolidated balance sheet. As of June 30, 2023, the components of the liabilities were as follows: Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses Employee (1) Balance as of January 1, 2023 $ - Restructuring expenses- Sales and Marketing 566 Restructuring expenses- Research and Development 477 Restructuring expenses- General and Administrative 474 Restructuring expenses Cash payments (1,423 ) Liability included in accounts payable and accrued expenses at June 30, 2023 $ 94 (1) Employee severance and other benefits expenses were included in sales and marketing expenses, research and development expenses, and general and administrative expenses in the statements of comprehensive loss.

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern Uncertainty (Details Narrative) - USD ($) $ in Thousands	3 Months Ended					6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	May 17, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss	$ 2,997	$ 4,386	$ 5,140	$ 4,811		$ 7,383	$ 9,951
Net cash used in operating activities						7,300
Cash and cash equivalents	8,521					8,521			$ 14,042
Accumulated deficit	$ 148,734					148,734			$ 141,351
Proceeds from issuance of common stock						$ 121	$ 3,165
Common stock, shares issued	5,305,441					5,305,441		525,000	4,659,769
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued								3,617,012
Equity Distribution Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock sold, shares						119,000
Proceeds from issuance of common stock						$ 102
Proceeds from net of issuance costs						$ 19
Equity Distribution Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate of offering cost					$ 25,000

SCHEDULE OF ANTI-DILUTIVE EFFEC

SCHEDULE OF ANTI-DILUTIVE EFFECT (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,001,276	827,101	5,001,276	827,101
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	304,164	403,911	304,164	403,911
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,455	28,613	10,455	28,613
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,686,657	394,577	4,686,657	394,577

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2023	May 17, 2023	Dec. 31, 2022
Common stock, shares issued	5,305,441	525,000	4,659,769
Prefunded Warrant [Member]
Common stock, shares issued	3,617,012
Common Stock [Member]
Common stock, shares issued		4,142,012
Converted basis, shares	142,857

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Assets and Liabilities (Details) - Contingent Royalty Obligation [Member] - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation	$ 1,056
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent royalty obligation	$ 1,056	$ 1,212

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Value of Level 3 Contingent Royalty Obligation (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2022	$ 1,212
Change in estimated fair value of contingent royalty obligation	156
Balance at June 30, 2023	$ 1,056

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Rate of royalty payment	3%		3%
Fair value of the liability, description	The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $95 and a 2% increase in the discount rate would decrease the liability by $86. Such amounts are based on highly sensitive estimates and actual results could result in material change in future periods
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
[custom:IncreaseDecreaseInDiscountRate]	28.50%	23%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 553	$ 697
Work-in-process	177	155
Finished goods	689	548
Inventory reserve	(596)	(401)
Inventory, net	823	999
Inventory, current	446	488
Inventory, non-current	$ 377	$ 511

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Inventory Disclosure [Abstract]
Impairment of inventory	$ 30	$ 0	$ 195	$ 159

Schedule of Fixed Assets Net (D

Schedule of Fixed Assets Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 3,332	$ 3,218
Less: accumulated depreciation and amortization	(2,123)	(1,893)
Fixed assets, net	1,209	1,325
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	171	171
Computers And Software [Member]
Property, Plant and Equipment [Line Items]
Total	321	321
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total	1,056	1,049
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,584	1,477
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 200	$ 200

Fixed assets, net (Details Narr

Fixed assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 113	$ 129	$ 230	$ 253

Schedule of Lease Cost and Supp

Schedule of Lease Cost and Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Leases
Operating lease cost, net of related party license fee	$ 2	$ 23	$ 18	$ 62
Variable lease cost	39	30	64	60
Total lease cost	41	$ 53	82	$ 122
Operating lease, right-of-use- asset	332		332		$ 428
Operating lease liabilities, current	243		243		245
Operating lease liabilities, net of current portion	79		79		178
Total lease liabilities	$ 322		$ 322		$ 423
Weighted average remaining lease term - operating leases	1 year 5 months 8 days		1 year 5 months 8 days		1 year 9 months 14 days
Weighted-average discount rate - operating leases	7.30%		7.30%		7.36%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
License fees	$ 60	$ 60	$ 109	$ 107
Office [Member] | Florida and Israel [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description			leases offices in Fort Lauderdale, Florida and Israel which expire in November 2024 and December 2023
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Operating lease, description			leases vehicles under operating leases that expire at various dates through 2025

Schedule of Interest Expense fo

Schedule of Interest Expense for Loan (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Debt Disclosure [Abstract]
Contractual interest expense	$ 224	$ 470
Amortization of debt issuance costs	61	123
Total interest expense	$ 285	$ 593

Schedule of Future Principal Pa

Schedule of Future Principal Payments of Convertible Note (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Less long-term debt, current	$ 2,694	$ 2,532
Long- term debt, net of current portion	3,198	$ 4,589
Convertible Note [Member]
Short-Term Debt [Line Items]
2023 (remaining 6 months)
2024
2025	4,000
Total future principal payments	4,000
Less unamortized debt issuance costs	(80)
Total balance	3,920
Long-Term Debt [Member]
Short-Term Debt [Line Items]
2023 (remaining 6 months)	1,389
2024	2,983
2025	1,601
Total future principal payments	5,973
Total balance	5,892
End of loan payments	140
Less unamortized debt issuance costs of current portion of long-term debt	(151)
Less unamortized debt issuance costs of non-current portion of long-term debt	(70)
Less long-term debt, current	2,694
Long- term debt, net of current portion	$ 3,198

Convertible Note and Long-Ter_3

Convertible Note and Long-Term Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
	Jul. 16, 2021	Jun. 30, 2023	Dec. 31, 2021	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exercise price		$ 0.0001
Long term debt		$ 2,694		$ 2,532
Tranche C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 3,000		$ 3,000
Kreos Loan Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 12,000
Debt instrument, interest rate		7.75%
Debt instrument, convertible, conversion price		$ 28
Warrant issued to purchase common shares	9,547
Exercise price	$ 20.948
Fair value of warrant		$ 165
Advance payment		845
Payments of debt issuance costs		540
Advance payments for debt discount		274
Long term debt		140
Kreos Loan Agreement [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Advance payment		$ 165
Kreos Loan Agreement [Member] | Tranche A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 4,000
Kreos Loan Agreement [Member] | Tranche B [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment, principal	$ 5,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Manufacturing costs	$ 38

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jan. 31, 2020
License fee	$ 60		$ 60	$ 109	$ 107
Minimum [Member]
License fee				$ 212
Maximum [Member]
License fee		$ 270
Shared Space Agreements [Member] | Orchestra Bio Med Inc [Member]
Ownership percentage						500%

Schedule of Stock-based Compens

Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 49	$ 461	$ 271	$ 982
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	21	100	80	197
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total		65	1	123
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 28	$ 296	$ 190	$ 662

Schedule of Stock Option and Wa

Schedule of Stock Option and Warrants (Details) - $ / shares		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Offsetting Assets [Line Items]
Shares underlying options, forfeited		0	(26)
Warrant [Member]
Offsetting Assets [Line Items]
Shares Underlying Warrants, Outstanding beginning		393,261
Weighted Average Exercise Price, Outstanding beginning		$ 50.86
Shares Underlying Warrants, granted	[1]	7,966,125
[custom:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantedPrice]		$ 0.40
Shares Underlying Warrants, expired		(55,717)
Weighted Average Exercise Price, granted		$ 100.45
Shares Underlying Warrants, forfeited
Weighted Average Exercise Price, forfeited
Shares Underlying Warrants, outstanding ending		8,303,669
Weighted Average Exercise Price, outstanding ending		$ 0.61
Shares Underlying Warrants, exercisable		8,303,669
Weighted Average Exercise Price, exercisable		$ 0.61
Equity Option [Member]
Offsetting Assets [Line Items]
Shares underlying options, outstanding beginning		400,137
Weighted average exercise price, outstanding beginning		$ 42.69
Shares underlying options, granted
Weighted average exercise price, granted
Shares underlying options, expired		(46,132)
Weighted average exercise price, expired		$ 42.87
Shares underlying options, forfeited		(49,841)
Weighted average exercise price, forfeited		$ 13.45
Shares underlying options, outstanding ending		304,164
Weighted average exercise price, outstanding ending		$ 47.45
Shares underlying options, exercisable		278,971
Weighted average exercise price, exercisable		$ 50.43
[1]Includes 3,617,012 0.0001

Schedule of Stock Option and _2

Schedule of Stock Option and Warrants (Details) (Parenthetical)	Jun. 30, 2023 $ / shares shares
Exercise price | $ / shares	$ 0.0001
Warrant [Member]
Warrant, shares | shares	3,617,012

Share-based compensation (Detai

Share-based compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				6 Months Ended
	Aug. 14, 2023	May 19, 2023	May 17, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 29, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 0.0001
Share based compensation plan modification, incremental cost				0	26
Common stock, shares issued			525,000	5,305,441		4,659,769
Private Placement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Net proceeds				$ 3,000
Proceeds from inclusive of issuance costs				500
Proceeds from exclusive of warrant issuance costs				$ 200
Share price			$ 0.125
Reduced exercise price			$ 0.72
Incremental fair value			$ 100
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock				3,617,012
Common stock, shares issued			3,617,012
Number of warrant purchase, shares			3,617,012
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price			$ 42.40
Common stock, shares issued			4,142,012
Shares Issued Price Per, Share			$ 0.845
Class of warrant or right outstanding			299,997
Reverse stock split			after the 1-to-20 reverse stock split
Prefunded Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price			$ 0.0001
Common stock, shares issued				3,617,012
Shares Issued Price Per, Share			$ 0.8449
Net proceeds			$ 3,000
Proceeds from inclusive of issuance costs			500
Proceeds from exclusive of warrant issuance costs			$ 200
Share price			$ 0.72
Fair value adjustment of warrants		$ 1,700
Common Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value adjustment of warrants				$ 1,500
Placement Agent Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price				$ 1.0563
Placement Agent Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value adjustment of warrants				$ 100
Prefunded Warrants [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of stock exercised	588,012
Services Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price							$ 10
Services Agreement [Member] | Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock							6,000
Exercise price							$ 56.60
Services Agreement [Member] | Replacement Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase of common stock							6,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average recognition period				8 months 4 days
Number of shares nonvested stock unit awards				10,455		20,278
Weighted average grant date fair value				$ 5.74		$ 18.62
Unamortization stock compensation				$ 50
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation for stock options				$ 243
Weighted-average recognition period				8 months 4 days
Share based compensation plan modification, incremental cost				49,841

Schedule of Restructuring Liabi

Schedule of Restructuring Liabilities included in Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
		Jun. 30, 2023	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Balance as of January 1, 2023	[1]
Restructuring expenses		$ 94
Cash payments		(416)	(1,423)	[1]
Liability included in accounts payable and accrued expenses at June 30, 2023	[1]	$ 94	94
Selling and Marketing Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	[1]		566
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	[1]		477
General and Administrative Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	[1]		$ 474
[1]Employee severance and other benefits expenses were included in sales and marketing expenses, research and development expenses, and general and administrative expenses in the statements of comprehensive loss.

Restructuring (Details Narrativ

Restructuring (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jan. 31, 2023	Jun. 30, 2023	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring description	the Company commenced a strategic restructuring program aimed at capital preservation. In April 2023, the Company approved the implementation of additional cost cutting measures, including an executive reorganization and other cuts in clinical expenses, in connection with its ongoing efforts to reduce operating expenses. In addition, the non-management members of the Board agreed to defer their Board fees until a future date
Restructuring charges		$ 94
Payments for restructuring		416	$ 1,423	[1]
Strategic Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 267	$ 1,517
[1]Employee severance and other benefits expenses were included in sales and marketing expenses, research and development expenses, and general and administrative expenses in the statements of comprehensive loss.